WPA
FENC icon

Wealth Preservation Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Wealth Preservation Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$31 – 370
2026
Q1 		$31 Buy
+5
New +$39 ﹤0.01% 990

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wealth Preservation Advisors's FENC Position: Q2 2026 in Review

Wealth Preservation Advisors sold out of Fennec Pharmaceuticals (FENC) in Q2 2026, closing a stake of 5 shares — an estimated $31 sold.

Wealth Preservation Advisors first reported a position in FENC in Q1 2026 and held it in 1 quarter. The position peaked at $31 in Q1 2026. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Wealth Preservation Advisors reported no remaining Fennec Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Wealth Preservation Advisors sold 5 Fennec Pharmaceuticals shares in Q2 2026, an estimated $31.
  • Wealth Preservation Advisors first reported a position in Fennec Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Wealth Preservation Advisors's Fennec Pharmaceuticals position peaked at $31 in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Wealth Preservation Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.